ABSTRACT

The American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine at the annual international conference. The 2021 Pulmonary Core Curriculum focuses on lung cancer and include risks and prevention, screening, nodules, therapeutics and associated pulmonary toxicities, and malignant pleural effusions. Although tobacco smoking remains the primary risk factor for developing lung cancer, exposure to other environmental and occupational substances, including asbestos, radon, and burned biomass, contribute to the...
LUNG CANCER RISK FACTORS AND PREVENTION

Oisin O’Corragain and Jamie Garfield

Lung cancer is the second most commonly diagnosed cancer and is the leading cause of cancer-related mortality worldwide. In 2020, there were 2.2 million new cases of lung cancer and 1.8 million lung cancer deaths, representing 11.4% of all cancer diagnoses and 18% of cancer deaths globally. Lung cancer is often detected at an advanced stage and has an estimated 5-year survival rate between 10% and 20% in most countries (1). Identification of risk factors and implementation of prevention strategies are key to decreasing the global impact of lung cancer.

Lung cancer incidence and mortality vary widely and largely reflect regional patterns of tobacco use. Approximately one-third of the global population used some form of tobacco in the year 2000. Rates of tobacco use decreased to 25% of the global population in 2015 and are projected to decline further to 20% in 2025 (2). In 2019, an estimated 50 million U.S. adults (20.8%) reported current tobacco use (3). Cigarette use has declined over the past decade, whereas electronic cigarette (e-cigarette) use has increased, with the highest prevalence of e-cigarette use being demonstrated among adolescents and young adults. In 2020, 3 million (19.6%) high school students reported current e-cigarette use (4). E-cigarette use has been strongly associated with cigarette smoking, including initiation of smoking in previous nonsmokers, raising concerns for increased tobacco use in a younger demographic (5).

Risk factors for lung cancer may be broadly divided into modifiable and nonmodifiable factors (Table 1). Tobacco smoking remains the leading risk factor for lung cancer, with current smoking status conferring relative risks of 6.99 and 7.33 for women and men, respectively (6). Exposure to radon is the leading cause of lung cancer among nonsmokers in North America (7). Other
increasingly recognized risk factors for lung cancer include environmental factors, such as air pollution, wildfires, and biomass exposure. Particulate matter with a diameter less than 10 μm is associated with lung cancer incidence (hazard ratio, 1.22 per 10 μg/m^3) (8). Cumulative exposure to smoke and particulate matter with a diameter less than 2.5 μm in wildland firefighters are associated with an increased lifetime risk of lung cancer (relative risk, 1.08–1.43) (9). Use of solid fuels and biomass for heating and cooking are important factors in developing countries, conferring a 70% increased risk of lung cancer (10).

Lung cancer prevention should focus on modifiable risk factors with exposure mitigation and abstinence. Occupational and household carcinogens, including radon and asbestos, should be avoided. Chemoprevention agents including glucocorticoids, myoinositol, prostacyclin analogs, thiazolidinediones, beta carotene, and aspirin have not been effective in preventing carcinogenesis (11). Genetic mutations that confer risk and biomarkers that predict the response to targeted agents are of growing importance. Comprehensive tobacco control and cessation strategies impact lung cancer risk.

Table 1. Lung cancer risk factors

| Modifiable | Nonmodifiable |
|------------|---------------|
| Tobacco use | Genetics and family history |
| Environmental or second-hand tobacco smoke | Prior radiation therapy |
| Diet and alcohol intake | Use of immunosuppressive medications |
| Environmental or occupational exposures | Chronic lung disease |
| Radon | Chronic obstructive pulmonary disease |
| Asbestos | Alpha-1 antitrypsin deficiency |
| Arsenic | Asthma |
| Beryllium | Fibrotic lung disease |
| Cadmium | Chronic infections |
| Silica | Mycobacteria |
| Vinyl chloride | C. pneumoniae |
| Nickel compounds | Human immunodeficiency virus |
| Chromium compounds | |
| Coal products | |
| Mustard gas | |
| Chloromethyl ethers | |
| Air pollution | |
| Wildfire exposure | |
| Biomass exposure | |

Definition of abbreviation: C. pneumoniae = Chlamydia pneumoniae.
Countries with tobacco demand-reduction measures have seen the greatest decline in tobacco prevalence. These measures include monitoring use and prevention, tobacco-free policies, evidence-based cessation therapies, advertising bans, and tobacco taxes (1). Even in countries where tobacco demand-reduction measures are advanced, tobacco use remains high in marginalized groups, which include those with lower socioeconomic status, coexistent substance use disorder or mental health disorders, and minority ethnicity. Risk factor identification and mitigation are especially important in these high-risk groups.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.

2. Commar A, Prasad V, d’Espaignet ET, Ong L. WHO global report on trends in prevalence of tobacco use 2000–2025. 3rd ed. Geneva, Switzerland: World Health Organization; 2019 [created 2019 Dec 18; accessed 2021 Feb 2]. Available from: https://www.who.int/publications-detail-redirect/who-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025-third-edition.

3. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults: United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:1736–1742.

4. Wang TW, Neff LJ, Park-Lee E, Ren C, Cullen KA, King BA. E-cigarette use among middle and high school students: United States, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1310–1312.

5. Hammond D, Reid JL, Cole AG, Leatherdale ST. Electronic cigarette use and smoking initiation among youth: a longitudinal cohort study. CMAJ 2017;189:E1328–E1336.

6. O’Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open 2018;8:e021611.

7. Krewski D, Labin JH, Zielinski JM, Alavanja M, Catalan VS, Field RW, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006;69:533–597.

8. Raaschou-Nielsen O, Andersen ZJ, Beelen R, Samoli E, Stafoggia M, Weinmayr G, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013;14:815–822.

9. Navarro KM, Kleinman MT, Mackay CE, Reinhardt TE, Balmes JR, Broyles GA, et al. Wildland firefighter smoke exposure and risk of lung cancer and cardiovascular disease mortality. Environ Res 2019;173:462–468.

10. Kirmo OP, Arya PH, Lam KB, Sorahan T, Ayres JG. Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. Eur Respir J 2012;40:1228–1237.

11. Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 2013;10:334–343.

12. González-Marrón A, Martín-Sánchez JC, Miró Q, Matilla-Santander N, Cartanyà-Hueso À, Mucci L, et al. Relation between tobacco control policies and population at high risk of lung cancer in the European Union. Environ Res 2019;179:108594.
LUNG CANCER SCREENING
Sahil Patel and Janelle V. Baptiste

Patients with lung cancer are frequently asymptomatic in the early stages of the disease when a surgical cure is most likely. Screening is therefore currently the best strategy for early detection of lung cancer. In 2011, the NLST (National Lung Screening Trial) demonstrated that screening with low-dose computed tomography (LDCT) resulted in a 20% relative reduction in lung cancer death (1). Nine years later, the Dutch-Belgian NELSON (Nederlands–Leuvens Longkanker Screenings Onderzoek) trial (2) confirmed the results of the NLST. At 10-year follow-up, lung cancer mortality was 24% lower in men and 33% lower in women who underwent LDCT than in those who had no screening (2). The use of nodule volume measurements and doubling time resulted in a higher sensitivity (93.5% vs. 92.5%) and specificity (98.3% vs. 73.4%) for detecting lung cancer than in the NLST (2).

These trials provided evidence supporting the development of several lung cancer screening guidelines (3–5). In 2021, the U.S. Preventive Services Task Force provided updated guidance, recommending screening in adults aged 50 to 80 years with a 20 pack-year smoking history (3). This differs from the 30 pack-years used in the NLST and expands its previous screening criteria. In contrast, the National Comprehensive Cancer Network offers an alternative guideline that targets adults with additional risk factors for lung cancer and combines this with a shorter smoking history requirement and expanded age criteria (Table 2) (6).

There is a critical gap in knowledge about how best to identify and select individuals at high risk for lung cancer and refer them for lung cancer screening. Several lung cancer risk prediction models have been developed to address this knowledge gap and the limitations of existing guidelines (7). One such model, the Prostate, Lung, Colorectal, and Ovarian Model 2012 (PLCOm2012) estimates 6-year lung cancer risk of ever-smokers aged 55–74 years by using several risk factors. When compared against NLST eligibility criteria, the PLCOm2012 significantly improved sensitivity and had a significantly higher positive predictive value without compromising specificity (8). Other models include the Bach model, Lung Cancer Risk Assessment Tool, and Lung Cancer Death Risk Assessment Tool, each with an online risk calculator (9). Several organizations incorporate one or more of these models in their screening guidelines. National Comprehensive Cancer Network guidelines now recommend screening smokers who have a PLCOm2012 6-year risk of 1.3% or greater. More prospective studies are needed to determine the effectiveness and the feasibility of implementing a risk-based screening program (7).

The use of artificial intelligence to develop algorithms capable of identifying LDCT features that may be specific to lung cancer is emerging as a promising tool for improving lung cancer screening. Coupling artificial intelligence with radiomics or integrating artificial intelligence into analysis of genomic, plasma biomarker, biopsy staining pattern, and other patient-derived data are currently under investigation (10).

Despite the progress made in establishing lung cancer screening with LDCT, the uptake in clinical practice has been slow and inconsistent, and patient adherence has been low (11). Improving integration into practice will require education and changes in clinical practice patterns. Combining smoking cessation interventions with annual LDCT may further increase the benefit of screening. Identifying the best strategies to incorporate smoking cessation is an active area of investigation (12).
Table 2. Eligibility criteria for lung cancer screening in asymptomatic patients

|                | Age (yr) | Smoking History (Pack-Years) | Years since Quitting Smoking | Other |
|----------------|----------|------------------------------|-----------------------------|-------|
| NLST           | 55–74    | ≥30                          | ≤15                         | The NLST excluded patients with symptoms suggesting lung cancer (hemoptysis, weight loss), patients who had a prior history of lung cancer or other threatening cancers in the previous 5 yr, patients with recent pneumonia, and those who had undergone a chest CT scan in the past 18 mo. |
| NELSON         | 55–74    | ≥15                          | <10                         |       |
| AATS           |          |                              |                             |       |
| Tier 1         | 55–79    | ≥30                          | –                           |       |
| Tier 2         | ≥50      | ≥20                          | –                           | Additional risk factor* |
| CHEST          | 55–77    | ≥30                          | <15                         | Lung cancer survivor for >5 yr |
| ACS            | 55–74    | ≥30                          | <15                         | –     |
| CMS            | 55–77    | ≥30                          | <15                         | –     |
| NCCN           |          |                              |                             |       |
| Group 1        | 55–77    | ≥30                          | <15                         |       |
| Group 2        | ≥50      | ≥20                          | –                           | ≥1 additional risk factor† |
| USPSTF         |          |                              |                             |       |
| 2013           | 55–80    | ≥30                          | <15                         | Discontinue screening when the individual exceeds the upper age criterion, has not smoked for >15 yr, has a comorbidity that substantially limits the life expectancy, or is unable or unwilling to have curative surgery. |
| 2021           | 50–80    | ≥20                          | <15                         |       |

Definition of abbreviations: AATS = American Association for Thoracic Surgery; ACS = American Cancer Society; CHEST = American College of Chest Physicians; CMS = Centers for Medicare and Medicaid Services; CT = computed tomography; NCCN = National Comprehensive Cancer Network; NELSON = Nederlands-Leuvens Longkanker Screenings Onderzoek; NLST = National Lung Screening Trial; USPSTF = U.S. Preventive Services Task Force. Adapted by permission from Reference 6. One pack-year indicates having smoked an average of one pack of cigarettes per day for 1 year.

*Additional risk factors for lung cancer defined by NCCN include cancer history, lung disease history, family history of lung cancer, radon exposure, and occupational exposure.

†Additional risk factors for lung cancer defined by the AATS include chronic obstructive pulmonary disease, environmental and occupational exposures, any prior cancer or thoracic radiation, and genetic or family history.

REFERENCES

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.

2. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382:503–513.
CURRENT APPROACH TO LUNG NODULES
Ngoc-Tram Ha and Van K. Holden

Approximately 1.5 million incidental pulmonary nodules are detected in the United States annually (1). Pulmonary nodules can be benign or malignant; therefore, risk stratification is essential in their evaluation and management.

The likelihood of malignancy can be determined on the basis of clinical and radiographic characteristics, including size, location, density, margins, and presence of calcification. Smooth, well-defined margins and popcorn-like calcifications are characteristics of benign nodules, whereas irregular margins and spiculation are associated with malignancy. Other important features include morphologic patterns, wall thickness, and growth rates. Although the doubling time of most malignant nodules ranges from 20 to 400 days, subsolid malignant nodules double between 400 and 800 days (2).

Current risk stratification models categorize nodules into low, intermediate, and high malignancy risk on the basis of the clinician pretest probability of malignancy (pCA) (Table 3). Use of these models can guide follow-up and management, but careful selection and application of available calculators are required. Models may not have been validated outside of the original patient population and may apply only to solid nodules (3).

Recent studies have focused on molecular biomarkers to further risk-stratify nodules, but additional clinical utility studies are...
needed (4). A bronchial genomic classifier demonstrated a 91% negative predictive value in current or former smokers with an intermediate pCA and inconclusive bronchoscopic biopsy results (5). Thus, a negative classifier result can down-classify the risk, resulting in less invasive procedures for benign lesions (6). An integrated plasma proteomic classifier (two plasma proteins and five clinical risk factors) has been evaluated in patients with undiagnosed 8- to 30-mm lung nodules and a low-to-moderate pCA of < 50% (7). A “likely benign” result accurately identified patients with benign nodules for up to 2 years of follow-up (8).

The Fleischner Society, the American College of Chest Physicians, the British Thoracic Society, and others have proposed guidelines on the management of incidentally identified pulmonary nodules (Table 4) (9–11). Lang-RADS from the American College of Radiology provides recommendations for screen-detected nodules (12), which the British Thoracic Society recommendations also address (10). On the basis of Fleischner Society guidelines, solid nodules measuring 6–8 mm are followed by computed tomography (CT) for 2 years, and subsolid nodules ≥ 6 mm are followed by CT for 5 years. A partly solid nodule with a solid component ≥ 6 mm is highly suspicious for malignancy.

A repeat CT examination at 3 months, positron emission tomography (PET)-CT, or tissue sampling can be considered for a solitary pulmonary nodule > 8 mm (9), depending on the pCA.

American College of Chest Physicians guidelines give further direction on the invasive management of solid, indeterminate nodules > 8 mm on the basis of the pCA and patient preference. For patients with a pCA of 5–65%, functional imaging with PET should be considered. Nonsurgical biopsy is suggested when the pCA and findings of imaging tests are discordant, the pCA is 10–60%, a benign diagnosis requiring specific medical

| Model                        | Study Population                                      | Number of Subjects | Prevalence of Malignancy | Nodule Size (mm) | Variables                                                                                             |
|------------------------------|-------------------------------------------------------|--------------------|--------------------------|------------------|--------------------------------------------------------------------------------------------------------|
| Mayo Clinic (1997)           | Incidental new PN detected with CXR                   | 629                | 23%                      | 4–30             | Age, smoking history, history of extrathoracic cancer ≥ 5 yr, nodule diameter, nodule spiculation, upper lobe location |
| VA (2007)                    | PNs seen at CXR and confirmed at CT and/or FDG-PET    | 375                | 54%                      | 7–30             | Age, smoking history, time since quitting smoking, nodule diameter                                       |
| Herder (2005)                | Patients referred for FDG-PET                          | 106                | 57%                      | < 30             | Mayo Clinic model and FDG-PET avidity intensity (none, faint, moderate, intense)                       |
| BIMC (2015)                  | PN diagnosis with biopsy, or deemed benign if stable at imaging for ≥ 2 yr | 343                | 58%                      | 4–30             | Age, smoking, history of previous malignancy, nodule diameter, edges, nodule location, volume doubling time, minimum focal density, enhancement at contrast-enhanced CT, FDG-PET avidity |

Definition of abbreviations: BIMC = Bayesian Inference Malignancy Calculator; CT = computed tomography; CXR = chest X-ray; FDG-PET = fluorodeoxyglucose–positron emission tomography; PN = pulmonary nodule; VA = Department of Veterans Affairs.

Data are from Reference 3.
| Table 4. Management of incidentally detected pulmonary nodules |
|---------------------------------------------------------------|
| **CHEST 2013** | **BTS 2015** | **Fleischner Society 2017** |
| **Solitary solid nodules** | | |
| No follow-up | ≤4 mm in patients with no risk factors for lung cancer | <5 mm or ≤80 mm³ | <6 mm or ≤100 mm³ |
| **CT surveillance** | No risk factors: | | |
| | >4 mm to 6 mm: 12 mo | ≥5 mm to ≤8 mm or ≥80 mm³ to <300 mm³ | Low risk: 6–12 mo, then consider at 18–21 mo |
| | >6 mm to 8 mm: 6–12 mo, then again at 18–24 mo | ≥8 mm or ≥300 mm³ and pCA <10% using the Brock model | High risk: 6–12 mo, then again at 18–21 mo |
| 1+ risk factors: | 5–6 mm | | |
| | ≤4 mm: 12 mo | CT at 12 mo, then management based on volume doubling time | |
| | >4 mm to 6 mm: 12 mo, then again at 18–24 mo | ≥6 mm or ≥80 mm³ | |
| | >6 mm to 8 mm: 3–6 mo, then at 9–12 mo and at 24 mo | CT at 3 mo, then management based on volume doubling time | |
| **CT at 3 mo, PET-CT, or tissue sampling** | >8 mm | ≥8 mm or ≥300 mm³ and pCA ≥10% using the Brock model | >8 mm or ≥250 mm³ |
| | <5% pCA: CT at 3–6, 9–12, and 18–24 mo | PET-CT and risk assess using Herder model | |
| | 5–65% pCA: PET | <10% pCA: CT surveillance | |
| | >65% pCA: surgical diagnosis | 10–70% pCA: biopsy | |
| Note there are additional recommendations on when to obtain nonsurgical or surgical biopsy. | | | |
| **Solitary pure ground-glass nodules** | No follow-up | ≤5 mm | <5 mm | <6 mm or ≤100 mm³ |
treatment is suspected, or the patient desires proof of a malignant diagnosis before surgery. Surgical intervention is recommended when the pCA is $>65\%$, the nodule is intensely hypermetabolic on PET images, the nonsurgical biopsy results are suspicious for malignancy, or the patient prefers undergoing a definitive diagnostic procedure. The risks and benefits of management strategies are discussed with the patient, and their preferences are elicited for shared decision-making regarding the optimal approach (11). The patient’s candidacy for surgery and the feasibility of nonsurgical biopsies (e.g., percutaneous vs. bronchoscopic) are also considered, depending on the availability of resources and expertise. Robotically assisted bronchoscopy is an evolving technology, and additional studies evaluating its diagnostic yield and clinical impact are needed.

**REFERENCES**

1. Gould MK, Tang T, Liu IL, Lee J, Zheng C, Danforth KN, et al. Recent trends in the identification of incidental pulmonary nodules. *Am J Respir Crit Care Med* 2015;192:1208–1214.

2. Patel VK, Naik SK, Naidich DP, Travis WD, Weingarten JA, Lazzaro R, et al. A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules. Part 1: radiologic characteristics and imaging modalities. *Chest* 2013;143:825–839.
3. Choi HK, Ghobrial M, Mazzone PJ. Models to estimate the probability of malignancy in patients with pulmonary nodules. *Ann Am Thorac Soc* 2018;15:1117–1126.

4. Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, et al.; ATS Assembly on Thoracic Oncology. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement. *Am J Respir Crit Care Med* 2017;196:e15–e29.

5. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al.; AEGIS Study Team. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. *N Engl J Med* 2015;373:243–251.

6. Vachani A, Whitney DH, Parsons EC, Lenburg M, Ferguson JS, Silvestri GA, et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. *Chest* 2016;150:210–218.

7. Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, et al.; PANOPTIC Trial Team. Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest* 2018;154:491–500.

8. Tanner NT, Springmeyer SC, Porter A, Jett JR, Mazzone P, Vachani A, et al. Assessment of integrated classifier’s ability to distinguish benign from malignant lung nodules: extended analyses and 2-year follow-up results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest* 2021;159:1283–1287.

9. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. *Radiology* 2017;284:228–243.

10. Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al.; British Thoracic Society Pulmonary Nodule Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. *Thorax* 2015;70:ii1–ii54.

11. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143(5 Suppl):e93S–e120S.

12. Lung-RADS version 1.1. Reston, VA: American College of Radiology; 2019 [accessed 2021 Apr 20]. Available from: https://www.acr.org/-/media/ACR/Files/ACR/Guidelines/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf.

**LUNG CANCER THERAPEUTICS AND PULMONARY TOXICITIES**

Codi Fitzgerald and Guang-Shing Cheng

The approach to lung cancer treatment is determined by a variety of factors, including tumor histology, stage, and patient comorbidities. Surgical resection is preferred for early-stage non–small cell lung cancer (NSCLC); stereotactic radiotherapy may be considered for poor surgical candidates (1, 2). Treatment of advanced-stage NSCLC is often multimodal and may include chemoradiation, targeted therapies, and immunotherapy (1). Clinicians should have a high index of suspicion for treatment-related pulmonary toxicity in patients presenting with nonspecific symptoms of dyspnea, cough, fever, and exercise intolerance. This is particularly true for newer chemotherapeutic agents commonly associated with pulmonary toxicity.
Immune checkpoint inhibitors (ICIs) have emerged as first-line therapy for patients with advanced-stage lung cancer who do not have a molecular target for treatment. ICIs work by targeting cellular immune pathways that regulate tumor recognition and death (3, 4). ICI-related pneumonitis is a potentially life-threatening complication of therapy, with the time of onset ranging from days to months after the initiation of treatment (4). Molecular therapies, including tyrosine kinase inhibitors (TKIs), target oncogenic mutations in the EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), and RET (RET proto-oncogene) oncogenic proteins (1, 2). The TKIs are first-line therapies for patients who harbor these mutations, which

### Table 5. Pulmonary toxicities of lung cancer therapies

| Therapeutic Class | Patterns of Toxicity |
|-------------------|----------------------|
| **ICIs**: anti–PD-1 (pembrolizumab, nivolumab), anti–PD-L1 (durvalumab, avelumab, atezolizumab), anti–CTLA-4 (ipilimumab) | • Interstitial pneumonitis  
• Organizing pneumonia  
• Acute fibrinous organizing pneumonia  
• Radiation recall pneumonitis  
• Alveolar hemorrhage  
• Pleural effusions |
| **TKIs**: EGFR (erlotinib, gefitinib, afatinib), ALK (crizotinib, alectinib), BRAF (dabrafenib), MEK1 (trametinib) | • Interstitial pneumonitis  
• Organizing pneumonia  
• Diffuse alveolar damage  
• Alveolar hemorrhage  
• Pleural effusions  
• Obliterative bronchiolitis |
| Conventional chemotherapy: gemcitabine, paclitaxel, docetaxel, pemetrexed | • Interstitial pneumonitis  
• Organizing pneumonia  
• Diffuse alveolar damage  
• Alveolar hemorrhage  
• Acute eosinophilic pneumonia  
• Noncardiac pulmonary edema  
• Radiation recall pneumonitis  
• Pulmonary fibrosis  
• Pulmonary arterial hypertension |

*Definition of abbreviations: ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; ICI = immune checkpoint inhibitor; TKI = tyrosine kinase inhibitor.*
are more commonly identified in younger patients with adenocarcinoma and a limited smoking history (1). TKI-associated toxicities include acute pneumonitis, organizing pneumonia, and diffuse alveolar hemorrhage (5). In patients without molecular targets, conventional chemotherapy is offered (1, 2). Toxicities and the timing of onset vary by chemotherapeutic class (6). Common patterns of pulmonary toxicity are summarized in Table 5.

Stereotactic radiation therapy is used in both early- and advanced-stage NSCLC. Radiation-induced lung injury encompasses a spectrum of disease, including acute radiation pneumonitis and chronic fibrosis (7). Patients with lung cancer are at increased risk of radiation-induced lung injury compared with patients with other malignancies. Risk factors include the radiation dosage, underlying lung disease, and ongoing tobacco use (7). In addition, patients treated with chemoinmunotherapy are at risk of radiation recall pneumonitis manifesting as pulmonary infiltrates within the prior field of radiation (6, 7).

When pulmonary toxicity is suspected, CT of the chest should be performed. Patterns of radiographic injury are nonspecific and include ground-glass attenuation and reticular opacities (4). Bronchoscopy should be considered to exclude infection, alveolar hemorrhage, and cancer progression. Lymphocytosis or eosinophilia in bronchoalveolar lavage fluid may support a diagnosis of drug-induced toxicity; however, no definitive studies can confirm treatment-related pulmonary toxicity (6, 7). Treatment of adverse pulmonary events is largely based on expert recommendations (4, 8). Asymptomatic patients may be observed clinically. For patients with new or worsening symptoms and imaging findings consistent with ICI-related pneumonitis, therapy is typically discontinued. Corticosteroids may be initiated (1–2 mg/kg/d) and tapered over 6 weeks (4, 8). If there is no improvement with corticosteroids or there is evidence of rapidly progressive respiratory failure, additional therapies such as infliximab, intravenous immunoglobulin, and mycophenolate may be considered (4, 8). Decisions about rechallenging a patient with a particular agent should occur on a case-by-case basis, with consideration given to the severity of the previous reaction and alternatives for treatment. In general, patients with severe pneumonitis should not be rechallenged.

REFERENCES

1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299–311.

2. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019;94:1623–1640.

3. Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis: an official American Thoracic Society research statement. Am J Respir Crit Care Med 2019;200:e31–e43.

4. Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 2018;154:1416–1423.

5. Hong D, Zhang G, Zhang X, Liang X. Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e3008.
MALIGNANT PLEURAL EFFUSIONS
Max T. Wayne and Jose De Cardenas

Malignant pleural effusions (MPEs) affect nearly 15% of patients with cancer and are associated with a poor prognosis. Median survival ranges from 3 to 12 months, depending on the type of malignancy (1, 2). The diagnosis of MPE is usually confirmed by cytologic analysis of pleural fluid, which should be drained under ultrasound guidance (2). Cytologic analysis of the initial drainage has a sensitivity of close to 60% (3) for identification of MPE. This increases an additional 15% with a second sampling (2). Once the diagnosis of MPE is confirmed, management is determined by symptoms (Figure 1). For asymptomatic patients, therapeutic pleural interventions should be avoided, as the risk of complications outweighs any clinical benefit (2). The initial management of symptomatic patients should start with a large-volume thoracentesis. This can provide evidence of symptomatic improvement with drainage and be used to assess for expandable lung when coupled with pleural manometry (2). Although using pleural manometry may not reduce procedural complications (4), it can help differentiate between fully expandable lung and both entrapped lung and trapped lung, for which treatment options are more limited.

More than half of patients with MPE experience rapid fluid reaccumulation (i.e., within 1 mo) (5). Consequently, patients with a reasonable expected survival outcome should be evaluated for a definitive pleural procedure. This may

---

Figure 1. Treatment algorithm for malignant pleural effusion (MPE). *Consider pleural manometry and pleural fluid analysis: cell count and differential, chemistry (LDH [lactate dehydrogenase], protein, cholesterol, NT-proBNP [N-terminal pro b-type natriuretic peptide]), and cytology. Other pleural tests (e.g., flow cytometry, cultures, triglycerides) might be required, depending on the clinical scenario. **If the patient has a good performance status, expandable lung, and would prefer not to have a long-term indwelling pleural catheter (IPC), either IPC placement with daily drainage or IPC placement followed by talc pleurodesis can be considered.
reduce the total number of interventions required and may reduce the rate of procedural complications, improving symptoms and quality of life (5). Definitive procedures should be considered unless the prognosis is very poor, in which case repeat thoracentesis or management of dyspnea with opiates are reasonable options.

For patients with expandable lung, definitive treatment strategies include chemical and mechanical pleurodesis or indwelling pleural catheters (IPCs) (1). First-line treatment options are IPCs and chemical pleurodesis (6). IPCs are placed as an outpatient procedure, avoiding hospitalization for patients with a limited life expectancy, and they carry a lower risk of treatment failure. However, IPCs are associated with a higher risk of cellulitis and pleural space infection, at rates of 7.3% and 4.6%, respectively, than pleurodesis (2).

Most cases of IPC-related infection can be treated with antibiotic therapy without removal of the catheter, reserving removal for those who do not improve with antibiotics. IPCs result in spontaneous pleurodesis in 16–65% of patients. Rates of pleurodesis can be increased with daily drainage or concomitant outpatient talc slurry pleurodesis through the existing IPC (7, 8). Chemical pleurodesis for management of MPE should be performed only in cases of fully expandable lung. The most effective pleurodesis agent is talc, which can be administered either via a poudrage (insufflation during thoracoscopy) or slurry (via an existing pleural drain).

For the 30% of patients with MPE and unexpandable lung, treatment options are limited (2). In this clinical scenario, IPCs are recommended, given the low risk of procedural complications (1). In patients with loculated MPE, IPCs are also preferred. For these patients, intrapleural fibrinolytics may help with drainage and improve symptoms, although this is at the expense of an increased bleeding risk and a higher cost (1, 2, 9). Future work is needed to better guide treatment for this specific patient population.

**Author disclosures** are available with the text of this article at [www.atsjournals.org](http://www.atsjournals.org).

**REFERENCES**

1. Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. *Eur Respir J* 2018;52:1800349.

2. Feller-Kopman DJ, Reddy CB, DeCamp MM, Dickemper RL, Gould MK, Henry T, et al. Management of malignant pleural effusions: an official ATS/STS/STR clinical practice guideline. *Am J Respir Crit Care Med* 2018;198:839–849.

3. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. *Arch Bronconeumol* 2014;50:161–165.

4. Lentz RJ, Lerner AD, Pannu JK, Merrick CM, Roller L, Walston C, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. *Lancet Respir Med* 2019;7:447–455.

5. Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions. *Chest* 2018;153:438–452.

6. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet* 2017;389:299–311.
7. Wahidi MM, Reddy C, Yarmus L, Feller-Kopman D, Musani A, Shepherd RW, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions: the ASAP trial. *Am J Respir Crit Care Med* 2017;195:1050–1057.

8. Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. *N Engl J Med* 2018;378:1313–1322.

9. Thomas R, Piccolo F, Miller D, MacEachern PR, Chee AC, Huseini T, et al. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. *Chest* 2015;148:746–751.